Gilead's Kite earns second-line win for CAR-T Yescarta, setting up a battle over earlier blood cancer patients

Kite’s Yescarta boosted event free survival over a standard of care regimen of physicians’-choice salvage therapy followed by high-dose chemo plus a stem cell transplant in second-line relapsed or refractory large B cell lymphoma patients in a win the drugmaker is calling a “landmark” in CAR-T care, Kite said in a release.